Literature DB >> 17618793

Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor.

Kai-Hsi Hsu1, Ta-Ming Yang, Yan-Shen Shan, Pin-Wen Lin.   

Abstract

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal tract. Surgery remains the mainstay of curative treatment. Recurrence after surgery was frequent and was associated with poor prognosis. In this study, we tried to identify predictors of recurrence in resectable GISTs.
METHODS: Between January 1995 and December 2005, 100 patients undergoing surgical resection for GISTs in 2 hospitals were studied.
RESULTS: There were 67 gastric and 33 intestinal GISTs. Recurrence was noted in 11 patients (median follow-up of 43 months). Overall 5-year survival was 84%. Multivariate analysis demonstrated that tumor size > or = 10 cm was associated with higher recurrence rates (P = .032) and was the only independent poor prognostic factor for survival (P = .020).
CONCLUSIONS: We concluded that tumor size > or = 10 cm carried both a higher risk of recurrence and worse survival in resectable GISTs and could be considered an indicator for adjuvant therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17618793     DOI: 10.1016/j.amjsurg.2006.10.033

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  10 in total

1.  Totally laparoscopic resection of a very large gastric GIST.

Authors:  G Anania; L Dellachiesa; N Fabbri; L Scagliarini; G Ferrocci; A Pezzoli; G Resta
Journal:  G Chir       Date:  2013 Jul-Aug

2.  Outcome after curative resection of large (>or=10 cm) gastric gastrointestinal stromal tumors: how frequent is adjacent organ involvement and is concomitant distal pancreatectomy necessary?

Authors:  Brian K P Goh; Pierce K H Chow; Sittampalam M Kesavan; Wai-Ming Yap; Yaw-Fui A Chung; Wai-Keong Wong
Journal:  J Gastrointest Surg       Date:  2010-04       Impact factor: 3.452

3.  Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal.

Authors:  F Duffaud; S Salas; T Huyn; Jl Deville
Journal:  Clin Exp Gastroenterol       Date:  2010-05-12

4.  Recurring gastrointestinal stromal tumor with splenic metastasis.

Authors:  Ho Gun Kim; Seong Yeob Ryu; Jae Kyoon Joo; Hyo Kang; Jae Hyuk Lee; Dong Yi Kim
Journal:  J Korean Surg Soc       Date:  2011-11-25

5.  Profile of patients with gastrointestinal stromal tumors (GIST).

Authors:  Eduardo Marcucci Pracucho; Luiz Roberto Lopes; Renato Morato Zanatto; Karla Thaisa Tomal; Celso Roberto Passeri; Joel Roberto Sagioro Molan; Ari de Almeida Prado
Journal:  Arq Bras Cir Dig       Date:  2015 Apr-Jun

6.  Two staging systems for gastrointestinal stromal tumors in the stomach: which is better?

Authors:  Chul Hong Park; Gwang Ha Kim; Bong Eun Lee; Geun Am Song; Do Youn Park; Kyung Un Choi; Dae Hwan Kim; Tae Yong Jeon
Journal:  BMC Gastroenterol       Date:  2017-12-06       Impact factor: 3.067

7.  Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender.

Authors:  Pan Ran; Juan Li; Xingye Wu; Hao Yang; Jun Zhang
Journal:  Patient Prefer Adherence       Date:  2022-08-12       Impact factor: 2.314

8.  Preoperative predictors of malignant gastric submucosal tumor.

Authors:  Ho Goon Kim; Seong Yeob Ryu; Sang Kwon Yun; Jae Kyoon Joo; Jae Hyuk Lee; Dong Yi Kim
Journal:  J Korean Surg Soc       Date:  2012-07-25

9.  A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature.

Authors:  Mario Castillo-Sang; Salim Mancho; Albert W Tsang; Barbu Gociman; Babatunde Almaroof; Mohammed Y Ahmed
Journal:  World J Surg Oncol       Date:  2008-05-15       Impact factor: 2.754

Review 10.  The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers.

Authors:  Hariti Saluja; Christos S Karapetis; Susanne K Pedersen; Graeme P Young; Erin L Symonds
Journal:  Front Oncol       Date:  2018-07-24       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.